September 2024 in “Preprints.org” Hair protects the scalp from skin cancer by aiding immune defense.
April 2024 in “Rheumatology” A young woman with visual issues and other symptoms was diagnosed with lupus and antiphospholipid syndrome, and improved with treatment.
April 2024 in “Animal models and experimental medicine” PRP treatment helps hair growth and rebalances scalp bacteria in androgenetic alopecia patients.
March 2024 in “Journal of Endocrinological Investigation” Finasteride treatment in rats changed the expression of genes related to psychiatric and neurological functions, and these changes persisted after stopping the drug.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
April 2019 in “Journal of Investigative Dermatology” Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.
October 2018 in “Biomedical Journal of Scientific & Technical Research” Otoplasty can cause permanent hair loss if bandages are too tight.
April 2014 in “Emergency Medicine News” Thyroid storm is hard to diagnose due to vague symptoms but needs urgent attention.
June 2012 in “Springer eBooks” Skin changes can indicate starvation and nutritional deficiencies in anorexia nervosa.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
July 1987 in “Reactions (Auckland)” Oral minoxidil may slow male pattern baldness and cause body hair growth, but hair loss can happen after stopping it.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
February 1990 in “Journal of The American Academy of Dermatology” New skin treatments in 1987-1988 showed effectiveness for various conditions, but some had side effects or risks.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
1 citations
,
October 1974 in “Postgraduate medicine” New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
25 citations
,
December 1974 in “Clinical Pharmacology & Therapeutics” Propranolol affects heart rate and renin levels in minoxidil-treated patients.
January 2026 in “Journal of Materials Chemistry B” TA-Ado effectively promotes hair growth and reduces hair loss.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.